Optimizing Heart Failure Management

Overview
Heart failure (HF) represents a significant burden on healthcare systems worldwide, with its prevalence steadily rising due to aging populations and increasing rates of comorbidities such as diabetes and chronic kidney disease. Despite advances in medical science, gaps persist in the identification, diagnosis, and management of heart failure among healthcare providers, particularly in the cardiology and primary care settings.

This accredited microlearning program highlights key topics in HF in video episodes that are 7-10 minutes each. Each microlearning features peer-to-peer interviews or panel discussions with leading experts in the following episodes: (1) Earlier is Better: Identifying and Diagnosing HF Early in Disease Progression; (2) Partnering with Patients: Building Effective Communication and Support in HF Care; (3) A Practical Guide to Prescribing in HF; (4) HF Management for Patients with Comorbid Conditions; (5) Level Up Your Skills: Tailoring Management of HF.
Disclosure of Conflict of Interest
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Faculty
Barry Greenberg, MD has disclosed the following relevant financial relationships:
Consultant: Affinia, Akero, Anthemm Astellas,Axon, Boerhinger Ingelheim, Bristol Myers Squibb, Cellular Dynamics, Corvia, Cytokinetics, Duke, EBR Systems, EcoR1, Faraday, Impulse Dynamics, Intellia, Inventiva, Ionis, Jaan, Maxwell, Merck, Momentum, Secretome, SummaCor, Tenaya, Univ of Virginia, Viking, Windtree
Researcher: Rocket Pharma
Neil Skolnik, MD has disclosed the following relevant financial relationships:
Advisor: Abbott, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Genentech
GSK, Idorsia, Lilly, Novartis, Novo Nordisk, Sanofi, Sanofi Pasteur, Teva
Consultant: AstraZeneca, Boehringer Ingelheim, Lilly, Sanofi, Teva
Researcher: AstraZeneca, GSK, Novartis, Novo Nordisk
Speaker: Astellis, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Heartland, Lilly, Teva
Trina Huynh, PharmD has has disclosed the following relevant financial relationships:
Consultant: Biobridge Aerovate, Altavant, Bayer, Caremark, L.L.C., Corvista, Gossamer Bio, Janssen, Merck, United Therapeutics
Researcher: Aerovate, Altavant, Gossamer-Bio, Janssen, Merck, Sonovie
Jessica Lee Lin, MPAP has no financial relationships to disclose.
Melissa Mclenon, DNP, ACNP-BC has no financial relationships to disclose.
Karina Brown, BSN, RN has no financial relationships to disclose.
Monitor
Brian McDonough, MD has no financial relationships to disclose.
AKH Staff and Planners
Lynne Kolton Schneider, PhD, Medical Writer: has no financial relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, VP, Healthcare Continuing Education and Operations: has no financial relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
Target Audience
The intended audience for this activity includes cardiologists, primary care providers, and other healthcare professionals (including pharmacists, NPs, PAs, and nurses) in the cardiology and primary care settings.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Outline a strategy for the identification and diagnosis of patients with HF early in disease progression.
- Develop strategies for effective patient education, counseling, and shared decision making about HF diagnosis and management.
- Formulate individualized, patient-centered, comprehensive treatment plans for patients with HF.
Accreditation and Credit Designation Statements
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
0.75 ANCC contact hours
Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 0.75 contact hours.
Physician Associates
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .75 AAPA Category 1 CME credits. Approval is valid until Expiration Date 9/15/2025. PAs should only claim credit commensurate with the extent of their participation.
Nurse Practitioners
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083. This activity is approved for 0.75 contact hour(s) (which includes .25 hour(s) of pharmacology).
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at tbrignoni@akhcme.com.
Provider(s)/Educational Partner(s)
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
Commercial Support
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
System Requirements
- Supported Browsers (2 most recent versions):
- - Google Chrome for Windows, Mac OS, iOS, and Android
  - Apple Safari for Mac OS and iOS
  - Mozilla Firefox for Windows, Mac OS, iOS, and Android
  - Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 09/16/2024
Expiration Date: 09/15/2025